MapLight Therapeutics Inc（MPLT）财务数据MPLTMapLight Therapeutics Inc

Evaluating the bottom line, MapLight Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -445.24%, provide a clear picture of how effectively MPLT converts its operational activities into shareholder value.

In the context of the broader market, MPLT competes directly with industry leaders such as AUTL and OVID. With a market capitalization of $490.73M, it holds a leading position in the sector. When comparing efficiency, MPLT's gross margin of N/A stands against AUTL's 57.61% and OVID's 100.00%. Such benchmarking helps identify whether MapLight Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

MapLight Therapeutics has reported consistent net losses, with Q4 2025 net income at -79,548,000 USD and an EPS of -9.16, reflecting poor financial health. The forward P/E ratio is 0, indicating no earnings expected in the near future, and the current ratio is 16.52, suggesting good short-term liquidity but not enough to offset ongoing losses.